These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 6162265)

  • 1. [Possibilities for the evaluation of receptor sites in benign prostatic hyperplasia and carcinoma of the prostate (author's transl)].
    Fischer D; Gevers W; Bressel M
    Urologe A; 1980 Nov; 19(6):326-30. PubMed ID: 6162265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Demonstration of a progestin receptor in human benign prostatic hyperplasia and prostatic carcinoma.
    Gustafsson JA; Ekman P; Pousette A; Snochowski M; Högberg B
    Invest Urol; 1978 Mar; 15(5):361-6. PubMed ID: 76618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. pS2 (TFF1) expression in prostate carcinoma: correlation with steroid receptor status.
    Abdou AG; Aiad HA; Sultan SM
    APMIS; 2008 Nov; 116(11):961-71. PubMed ID: 19132993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptor versus erbB-1 and erbB-2 expression in human prostate neoplasms.
    Brys M; Stawinska M; Foksinski M; Barecki A; Zydek C; Miekos E; Krajewska WM
    Oncol Rep; 2004 Jan; 11(1):219-24. PubMed ID: 14654929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer.
    Heracek J; Hampl R; Hill M; Starka L; Sachova J; Kuncova J; Eis V; Urban M; Mandys V
    Steroids; 2007 Apr; 72(4):375-80. PubMed ID: 17368496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer.
    Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Bostwick DG
    J Urol; 1999 Apr; 161(4):1229-32. PubMed ID: 10081875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The expression of thrombospondin-1 in benign prostatic hyperplasia and prostatic intraepithelial neoplasia is decreased in prostate cancer.
    Vallbo C; Wang W; Damber JE
    BJU Int; 2004 Jun; 93(9):1339-43. PubMed ID: 15180634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of the KAI1 protein in benign prostatic hyperplasia and prostate cancer.
    Ueda T; Ichikawa T; Tamaru J; Mikata A; Akakura K; Akimoto S; Imai T; Yoshie O; Shiraishi T; Yatani R; Ito H; Shimazaki J
    Am J Pathol; 1996 Nov; 149(5):1435-40. PubMed ID: 8909232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer.
    Nelson JB; Chan-Tack K; Hedican SP; Magnuson SR; Opgenorth TJ; Bova GS; Simons JW
    Cancer Res; 1996 Feb; 56(4):663-8. PubMed ID: 8630991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Flow cytometric determination of DNA distribution patterns of malignant and benign tumors of the prostate (author's transl)].
    Lämmel A; Roters M; Kastendieck H; Becker H
    Urologe A; 1981 Nov; 20(6):400-4. PubMed ID: 6171922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis.
    Antunes AA; Leite KR; Sousa-Canavez JM; Camara-Lopes LH; Srougi M
    J Urol; 2009 Feb; 181(2):594-600. PubMed ID: 19084862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variation of M3 muscarinic receptor expression in different prostate tissues and its significance.
    Song W; Yuan M; Zhao S
    Saudi Med J; 2009 Aug; 30(8):1010-6. PubMed ID: 19668880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Organ culture of human tissue as study model of hormonal and pharmacological regulation of benign prostatic hyperplasia and of prostatic cancer].
    Janssen T; Kiss R; Schulman C
    Acta Urol Belg; 1995 Mar; 63(1):7-14. PubMed ID: 7537011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Studies on sex hormone-binding globulin in the prostate].
    Jiang H; Chen Z
    Zhonghua Nan Ke Xue; 2004 Jun; 10(6):443-4, 448. PubMed ID: 15267211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
    Zhao Z; Liu J; Li S; Shen W
    Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The expression of pluripotency marker Oct 3/4 in prostate cancer and benign prostate hyperplasia.
    Monsef N; Soller M; Isaksson M; Abrahamsson PA; Panagopoulos I
    Prostate; 2009 Jun; 69(9):909-16. PubMed ID: 19274762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
    Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
    Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of age, benign prostatic hyperplasia, and cancer on prostate-specific antigen level.
    Punglia RS; D'Amico AV; Catalona WJ; Roehl KA; Kuntz KM
    Cancer; 2006 Apr; 106(7):1507-13. PubMed ID: 16518812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential expression of TRAIL and its receptors in benign and malignant prostate tissues.
    Sanlioglu AD; Koksal IT; Ciftcioglu A; Baykara M; Luleci G; Sanlioglu S
    J Urol; 2007 Jan; 177(1):359-64. PubMed ID: 17162091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The expression of neuropeptides in hyperplastic and malignant prostate tissue and its possible clinical implications.
    Yu DS; Hsieh DS; Chen HI; Chang SY
    J Urol; 2001 Sep; 166(3):871-5. PubMed ID: 11490236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.